Most recent studies have focused on exogenous growth factors, including somatostatin,11 glutamine and growth hormone,12 epidermal growth factors,13 insulin-like growth factor-I,14 glucagon-like peptide 2,15 and hepatocyte growth factors.16 However, for some SBS patients, the residual intestines are critically short, therefore the outcomes are not very satisfactory. This evidence concerns the gene IGF1 and macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.